The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...

The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...

The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...

For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global ...

Medtronic gets US FDA nod for the world’s first adaptive deep brain stimulation system for people with Parkinson’s disease: Galway, Ireland Saturday, March 1, 2025, 09:00 Hrs ...

For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...

There is no cure for Parkinson's, and over one million people have the disease in the United States alone. However, deep brain stimulation (DBS) has been used to treat this and other neurological ...

The FDA has approved Medtronic's Brainsense Adaptive deep brain stimulation for patients with Parkinson's disease. The technology is designed to adjust therapy in real time based on a patient's brain ...

A decade after scientists at The Picower Institute for Learning and Memory at MIT first began testing whether sensory ...